ProShare Advisors
ZBIO

ProShare Advisors’s Zenas BioPharma ZBIO Stock Holding History

ProShare Advisors’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,820
Closed -$211K – 2054
2025
Q4 		$211K Buy
+5,820
New +$191K ﹤0.01% 1686

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

ProShare Advisors's ZBIO Position: Q1 2026 in Review

ProShare Advisors sold out of Zenas BioPharma (ZBIO) in Q1 2026, closing a stake of 5,820 shares — an estimated $211K sold.

ProShare Advisors first reported a position in ZBIO in Q4 2025 and held it in 1 quarter. The position peaked at $211K in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • ProShare Advisors reported no remaining Zenas BioPharma position as of Q1 2026 after selling out during the quarter.
  • ProShare Advisors sold 5,820 Zenas BioPharma shares in Q1 2026, an estimated $211K.
  • ProShare Advisors first reported a position in Zenas BioPharma in Q4 2025 and held it in 1 quarter.
  • ProShare Advisors's Zenas BioPharma position peaked at $211K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.